Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Haemonetics

HAE Healthcare Unknown Updated July 31, 2026
$85.61
52W $47.32 – $87.32
47/100
$3.89B
41.9
0.52
AI Committee Verdict
Watch
Conviction: Moderate · 71% agreement · 7 analysts
+1.0%
-1.3%
0.78:1
Moderate

Is HAE Bullish or Bearish?

Mixed. Innellis AI committee rates Haemonetics (HAE) Watch with a composite score of 47/100 , based on 7 analysts with 71% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +13.28 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -6.72 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee sees neither a compelling opportunity nor a clear risk at this stage. Conditions remain neutral — patience is warranted.

Bull & Bear Case

Bull Case
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • P/E of 39.2 is moderate-to-rich — Value
  • Debt-to-equity of 1.54 adds balance-sheet risk to the value case — Value
  • Revenue declining -2.0% YoY -- this is not a growth story right now — Growth
  • EPS declining -38.7% YoY despite any revenue growth — Growth
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • RSI at 80 is in overbought territory — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
47/100
Agreement
71%
Analysts
7
Conviction
Moderate
Sector Rank
Top 100%
of 93 Healthcare peers
Value Analyst neutral
43 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 39.2 is moderate-to-rich
Growth Analyst bearish
38 / 100 · High confidence
Growth story is weak, decelerating, or inconsistent
+ 4 consecutive earnings beats -- consistent execution
− Revenue declining -2.0% YoY -- this is not a growth story right now
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 80 is in overbought territory
Risk Analyst bearish
32 / 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 1.54) amplifies downside in a stress scenario
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst neutral
53 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 47.4 to 46.7.

Analyst-level changes:
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Risk Analyst: +1 bearish signal(s).
  • Technical Analyst: +1 bearish signal(s).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
81.7
Overbought
MACD Histogram
0.649
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$84.46
Resistance
$86.50
Bollinger %B
1.00
Inside Bands
Price vs Moving Averages
EMA 9
$82.08 Above
EMA 21
$79.18 Above
EMA 50
$74.54 Above
EMA 200
$68.22 Above

Fundamental Analysis

Valuation
49
Growth
73
Profitability
0
Financial Health
74
Cash Flow
37
Valuation
P/E Ratio 41.9×
P/B Ratio 4.97×
PEG Ratio -1.08
Dividend Yield 0.00%
52W High $87.32
52W Low $47.32
Quality & Growth
ROE 12.2%
ROA 4.1%
Gross Margin 57.3%
Operating Margin 18.1%
Revenue Growth YoY
Debt / Equity 1.54
AI Fundamental Assessment
P/E ratio of 41.9 (rich relative to a 15-40x range); Price-to-book of 5.0x; PEG ratio of -1.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.0%; Net margin of 0.1%; Gross margin of 0.6%; Current ratio of 2.95 (healthy short-term liquidity); Debt-to-equity of 1.54; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (5.63); Most recent quarter beat estimates by 0.4%; 4 consecutive earnings beats; EPS growth decelerating (+3.1% -> -1.5% QoQ); Analyst estimates rising over recent quarters
Get the Full HAE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore HAE Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime